KEZAR LIFE SCIENCES INC (KZR) Stock Price, Quote, News and Overview
NASDAQ:KZR - Nasdaq - US49372L2097 - Common Stock - Currency: USD
KZR Quote, Performance and Key Statistics
4.39
+0.06 (+1.39%)
The current stock price of KZR is 4.39 USD. In the past month the price decreased by -10.04%. In the past year, price decreased by -48.8%.
KZR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.86 | 342.62B | ||
| AMGN | AMGEN INC | 14.67 | 156.29B | ||
| GILD | GILEAD SCIENCES INC | 13.54 | 130.63B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1732.24 | 129.14B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.16 | 63.76B | ||
| ARGX | ARGENX SE - ADR | 337.06 | 39.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.41B | ||
| ONC | BEIGENE LTD-ADR | N/A | 28.33B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.95B | ||
| NTRA | NATERA INC | N/A | 20.43B | ||
| BIIB | BIOGEN INC | 7.33 | 17.66B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.24B |
Related stock screener links
About KZR
Company Profile
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2018-06-21. The firm's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The firm is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.
Company Info
KEZAR LIFE SCIENCES INC
4000 Shoreline Ct Ste 300
South San Francisco CALIFORNIA 94080 US
CEO: John Fowler
Employees: 58
Company Website: https://kezarlifesciences.com/
Investor Relations: https://ir.kezarlifesciences.com/
Phone: 16508225600
KEZAR LIFE SCIENCES INC / KZR FAQ
What is the stock price of KEZAR LIFE SCIENCES INC today?
The current stock price of KZR is 4.39 USD. The price increased by 1.39% in the last trading session.
What is the ticker symbol for KEZAR LIFE SCIENCES INC stock?
The exchange symbol of KEZAR LIFE SCIENCES INC is KZR and it is listed on the Nasdaq exchange.
On which exchange is KZR stock listed?
KZR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KEZAR LIFE SCIENCES INC stock?
10 analysts have analysed KZR and the average price target is 12.75 USD. This implies a price increase of 190.43% is expected in the next year compared to the current price of 4.39. Check the KEZAR LIFE SCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KEZAR LIFE SCIENCES INC worth?
KEZAR LIFE SCIENCES INC (KZR) has a market capitalization of 32.09M USD. This makes KZR a Nano Cap stock.
How many employees does KEZAR LIFE SCIENCES INC have?
KEZAR LIFE SCIENCES INC (KZR) currently has 58 employees.
What are the support and resistance levels for KEZAR LIFE SCIENCES INC (KZR) stock?
KEZAR LIFE SCIENCES INC (KZR) has a resistance level at 4.56. Check the full technical report for a detailed analysis of KZR support and resistance levels.
Should I buy KEZAR LIFE SCIENCES INC (KZR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KZR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KZR, evaluating the profitability, health, valuation and growth aspects
- KEZAR LIFE SCIENCES INC (KZR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KEZAR LIFE SCIENCES INC (KZR) Sales and EPS estimates to see what analysts future expectations are.
- KEZAR LIFE SCIENCES INC (KZR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KEZAR LIFE SCIENCES INC (KZR) Insider and Institutional Ownership to learn about the owners and their transactions.
- KEZAR LIFE SCIENCES INC (KZR) Stock Chart to make your own analysis
- KEZAR LIFE SCIENCES INC (KZR) Latest news and press-releases to stay up to date.
Does KEZAR LIFE SCIENCES INC (KZR) stock pay dividends?
KZR does not pay a dividend.
When does KEZAR LIFE SCIENCES INC (KZR) report earnings?
KEZAR LIFE SCIENCES INC (KZR) will report earnings on 2025-05-07, after the market close.
What is the Price/Earnings (PE) ratio of KEZAR LIFE SCIENCES INC (KZR)?
KEZAR LIFE SCIENCES INC (KZR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.25).
What is the Short Interest ratio of KEZAR LIFE SCIENCES INC (KZR) stock?
The outstanding short interest for KEZAR LIFE SCIENCES INC (KZR) is 1.09% of its float. Check the ownership tab for more information on the KZR short interest.
KZR Technical Analysis
KZR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KZR. While KZR seems to be doing ok healthwise, there are quite some concerns on its profitability.
KZR Financial Highlights
Over the last trailing twelve months KZR reported a non-GAAP Earnings per Share(EPS) of -11.25. The EPS decreased by -697.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -57.88% | ||
| ROE | -71.62% | ||
| Debt/Equity | 0.04 |
KZR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to KZR. The Buy consensus is the average rating of analysts ratings from 10 analysts.